Bioenvision to Present at the 24th Annual JPMorgan Healthcare Conference

Bioenvision, Inc. (Nasdaq: BIVN) announced today that
Dr. Christopher B. Wood, Chairman and Chief Executive Officer of the
Company, will present at the 24th Annual JPMorgan Healthcare
Conference, Tuesday, January 10, 2006, at 11:30 am PST in San
Francisco. An audio webcast of the presentation will be available to
all interested parties at Bioenvision's website (www.bioenvision.com)
or directly accessed by the following link:
http://equityconferences.jpmorgan.com.

   About clofarabine

   Clofarabine is a next generation purine nucleoside analog. This
class of drugs inhibits DNA production necessary for cancer cell
growth. Bioenvision and Genzyme Corporation (Nasdaq: GENZ) are
co-developing clofarabine. Bioenvision holds an exclusive worldwide
license for clofarabine (outside Japan and Southeast Asia).
Bioenvision granted an exclusive sublicense to Genzyme to develop and
commercialize clofarabine for cancer indications in the US and Canada.
Bioenvision holds an exclusive license in the US and Canada for all
non-cancer indications and an exclusive, irrevocable option to develop
and market clofarabine for all human applications in Japan and
Southeast Asia.
   Bioenvision originally obtained clofarabine development and
commercialization rights under patents held by Southern Research
Institute.
   Clofarabine has been granted orphan drug designation for the
treatment of adult and pediatric ALL and AML in the U.S. and Europe.
In the U.S., orphan drug status extends market exclusivity for seven
years. The FDA also recently granted an additional six months market
exclusivity to clofarabine under the Best Pharmaceuticals for Children
Act. In Europe, the designation provides marketing exclusivity for 10
years following Market Authorization. In December 2004, FDA approved
the use of clofarabine for treatment of pediatric patients 1 to 21
years old with relapsed or refractory ALL after at least two prior
regimens.
   In Europe, Bioenvision filed a marketing authorization application
(MAA) for clofarabine via the Centralized Procedure in July 2004.

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: clofarabine (in co-development
with Genzyme Corporation), Modrenal(R) (for which Bioenvision has
obtained regulatory approval for marketing in the United Kingdom for
the treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products in clinical trials.
Bioenvision is also developing anti-infective technologies, including
the OLIGON technology; an advanced biomaterial that has been
incorporated into various FDA approved medical devices. For more
information on Bioenvision please visit our Web site at
www.bioenvision.com.

   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.